Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Pinebridge Investments L.P.

Pinebridge Investments L.P. increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 42.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 39,167 shares of the biopharmaceutical company's stock after purchasing an additional 11,716 shares during the period. Pinebridge Investments L.P.'s holdings in Halozyme Therapeutics were worth $1,873,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in HALO. Virtu Financial LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at $434,000. World Investment Advisors LLC purchased a new stake in Halozyme Therapeutics during the third quarter worth about $3,293,000. Tidal Investments LLC increased its stake in Halozyme Therapeutics by 265.5% during the third quarter. Tidal Investments LLC now owns 20,576 shares of the biopharmaceutical company's stock worth $1,178,000 after purchasing an additional 14,947 shares during the period. Castellan Group lifted its position in shares of Halozyme Therapeutics by 4.5% during the third quarter. Castellan Group now owns 113,798 shares of the biopharmaceutical company's stock worth $6,514,000 after purchasing an additional 4,876 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its stake in shares of Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock valued at $22,282,000 after purchasing an additional 74,173 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,697 shares of company stock valued at $1,558,052 in the last three months. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Up 1.9 %

Halozyme Therapeutics stock traded up $1.16 during mid-day trading on Friday, hitting $61.19. The company had a trading volume of 1,098,414 shares, compared to its average volume of 1,443,747. The stock has a market cap of $7.56 billion, a price-to-earnings ratio of 17.84, a PEG ratio of 0.42 and a beta of 1.26. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 1 year low of $40.19 and a 1 year high of $66.00. The business has a fifty day moving average of $60.79 and a 200 day moving average of $55.39.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on HALO shares. JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. HC Wainwright restated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday, April 25th. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Benchmark reissued a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $62.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.